Danielle Antalffy's questions to BOSTON SCIENTIFIC (BSX) leadership • Q3 2025
Question
Danielle Antalffy of UBS Group AG questioned Boston Scientific's CRM business performance, noting it has grown below market while a competitor projects double-digit growth. She asked about the expected growth cadence with upcoming new product cycles, including the Denali platform, EMPOWER leadless pacemaker, and Elutia BioEnvelope assets.
Answer
Chairman and CEO Mike Mahoney highlighted strong performance in the LUX ICM device. He and CMO Dr. Ken Stein detailed the Denali platform, a complete refresh of implantable devices (Brady, high-voltage CRT, SICD) launching in late H2 2026 and throughout the LRP, expected to strengthen core CRM. They also emphasized EMPOWER's potential in the leadless pacemaker market and as an SICD enabler, alongside the Elutia BioEnvelope acquisition for preventing postoperative complications and strong growth in conduction system pacing.